期刊文献+

以二唾液酸神经节苷脂为靶点对神经母细胞瘤行免疫治疗的研究进展 被引量:1

Research progress on disialoganglioside as target for immunotherapy of neuroblastoma
原文传递
导出
摘要 神经母细胞瘤(NB)是起源于神经嵴细胞的儿童常见颅外实体瘤。二唾液酸神经节苷脂(GD)类的GD2在NB中高度表达,但在正常组织中表达水平低且仅限于中枢神经系统、周围痛觉纤维以及皮肤黑色索细胞。因此GD2是NB免疫治疗的理想靶点。现就以GD2为靶点的NB免疫治疗的研究进展进行综述。 Neuroblastoma (NB), the common extracranial solid tumor of childhood, is thought to derive from neural crest cells. In disialoganglioside ( GD ) 2 is highly expressed on NB, whereas GD2 expression is weak and restricted to the central nervous system, peripheral pain fibers and skin melanocytes. Therefore, GD2 is an ideal antigen target for immunotherapy of NB. The research progress on GD2 as target for immunotherapy of NB was reviewed.
出处 《中华实用儿科临床杂志》 CAS CSCD 北大核心 2015年第15期1196-1198,共3页 Chinese Journal of Applied Clinical Pediatrics
关键词 神经母细胞瘤 神经节苷脂 免疫疗法 Neuroblastoma Ganglioside Immunotherapy
  • 相关文献

参考文献25

  • 1YoungJL, RiesLG, SilverbergE, et al.Cancer incidence, survival, and mortality for children younger than age 15 years[J].Cancer, 1986, 58(2Suppl):S598-602. 被引量:1
  • 2唐锁勤.高危神经母细胞瘤的治疗[J].中国当代儿科杂志,2014,16(2):103-107. 被引量:21
  • 3OhmiY, OhkawaY, TajimaO, et al.Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord[J].J Neuroinflammation, 2014, 11:61. 被引量:1
  • 4BattulaVL, ShiY, EvansKW, et al.Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis[J].J Clin Invest, 2012, 122(6):2066-2078. 被引量:1
  • 5XuJ, FanW, TuXX, et al.Neural ganglioside GD2(+) cells define a subpopulation of mesenchymal stem cells in adult murine bone marrow[J].Cell Physiol Biochem, 2013, 32(4):889-898. 被引量:1
  • 6CheungNK, CheungIY, KramerK, et al.Key role for myeloid cells:phase Ⅱ results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma[J].Int J Cancer, 2014, 135(9):2199-2205. 被引量:1
  • 7KushnerBH, ModakS, BasuEM, et al.Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody[J].Cancer, 2013, 119(15):2789-2795. 被引量:1
  • 8KushnerBH, KramerK, ModakS, et al.Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma:a phase I study[J].J Clin Oncol, 2011, 29(9):1168-1174. 被引量:1
  • 9YuAL, GilmanAL, OzkaynakMF, et al.Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J].N Engl J Med, 2010, 363(14):1324-1334. 被引量:1
  • 10LadensteinR, WeixlerS, BaykanB, et al.Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients:a SIOPEN Phase 1 study[J].MAbs, 2013, 5(5):801-809. 被引量:1

二级参考文献11

  • 1Mattano LA Jr,Moss TJ,Emerson SG. Sensitive detection of rare circulating neuroblastoma ceils by the reverse transcriptasepolymerase chain reaction[J].{H}CANCER RESEARCH,1992,(17):4701-4705. 被引量:1
  • 2Stram DO,Matthay KK,O'Leary M. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma:a report of two concurrent Children's Cancer Group studies[J].{H}Journal of Clinical Oncology,1996,(9):2417-2426. 被引量:1
  • 3Vogelzang N J,Benowitz SI,Adams S. Clinical cancer advances 2011:Annual Report on Progress Against Cancer from the American Society of Clinical Oncology[J].{H}Journal of Clinical Oncology,2012,(1):88-109. 被引量:1
  • 4Castel V,Tovar JA,Costa E. The role of surgery in stage Ⅳ neuroblastoma[J].{H}Journal of Pediatric Surgery,2002,(11):1574-1578. 被引量:1
  • 5Wilson JS,Gains JE,Moroz V. A systematic review of 1311-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma[J].{H}EUROPEAN JOURNAL OF CANCER,2013. 被引量:1
  • 6Kreissman SG,Seeger RC,Matthay KK. Purged versus non-purged peripheral blood stem-cell transplantation for highrisk neuroblastoma (COG A3973):a randomised phase 3 trial[J].{H}LANCET ONCOLOGY,2013,(10):999-1008. 被引量:1
  • 7Yu AL,Uttenreuther-Fischer MM,Huang CS. Phase Ⅰ trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma[J].{H}Journal of Clinical Oncology,1998,(6):2169-2180. 被引量:1
  • 8Handgretinger R,Anderson K,Lang P. A phase Ⅰ study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients withneuroblastoma[J].{H}EUROPEAN JOURNAL OF CANCER,1995,(2):261-267. 被引量:1
  • 9Yu AL,Gilman AL,Ozkaynak MF. Ami-GD2 antibody with GM-CSF,interleukin-2,and isotretinoin for neuroblastoma[J].{H}New England Journal of Medicine,2010,(14):1324-1334. 被引量:1
  • 10Morgenstern DA,Baruchel S,Irwin MS. Current and future strategies for relapsed neuroblastoma:challenges on the road to precision therapy[J].{H}Journal of Pediatric Hematology Oncology,2013,(5):337-347. 被引量:1

共引文献20

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部